Indacaterol + Control
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Conditions
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Trial Timeline
Feb 1, 2013 โ Sep 1, 2014
NCT ID
NCT01778062About Indacaterol + Control
Indacaterol + Control is a phase 3 stage product being developed by Novartis for Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01778062. Target conditions include Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01778062 | Phase 3 | Completed |
Competing Products
20 competing products in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |
| ASP015K | Astellas Pharma | Phase 1 | 33 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| ATG-F | Astellas Pharma | Approved | 85 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |